Bicycle Therapeutics Plc ADR [BCYC] stock prices are down -0.85% to $23.40 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCYC shares have gain 3.40% over the last week, with a monthly amount glided 13.92%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on September 06, 2024, when RBC Capital Mkts initiated its Outperform rating and assigned the stock a price target of $35. Previously, B. Riley Securities downgraded its rating to Neutral on August 07, 2024, and dropped its price target to $28. On September 11, 2023, upgrade upgraded it’s rating to Buy. Cowen started tracking the stock assigning a Outperform rating. Barclays initiated its recommendation with a Overweight and recommended $30 as its price target on July 28, 2022. In a note dated April 13, 2022, B. Riley Securities downgraded an Neutral rating on this stock and revised its target price from $62 to $33.
The stock price of Bicycle Therapeutics Plc ADR [BCYC] has been fluctuating between $12.54 and $28.20 over the past year. Currently, Wall Street analysts expect the stock to reach $65.33 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $23.40 at the most recent close of the market. An investor can expect a potential return of 179.19% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
The Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] reported sales of 39.59M for trailing twelve months, representing a drop of -18.04%. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -5.22%, Pretax Profit Margin comes in at -4.69%, and Net Profit Margin reading is -4.18%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.33 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.02 points at the first support level, and at 22.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 23.81, and for the 2nd resistance point, it is at 24.23.
Ratios To Look Out For
It’s worth pointing out that Bicycle Therapeutics Plc ADR [NASDAQ:BCYC]’s Current Ratio is 14.77. In addition, the Quick Ratio stands at 14.77 and the Cash Ratio stands at 13.81. Considering the valuation of this stock, the price to sales ratio is 40.75, the price to book ratio is 1.85.
Transactions by insiders
Recent insider trading involved Lee Kevin, CHIEF EXECUTIVE OFFICER, that happened on Oct 03 ’24 when 3212.0 shares were sold. CHIEF PROD & SUPPLY CHAIN OFF, Hannay Michael Charles Ferguso completed a deal on Oct 03 ’24 to sell 247.0 shares. Meanwhile, CHIEF TECHNOLOGY OFFICER Skynner Michael sold 972.0 shares on Oct 03 ’24.
